Based on this information we proposed the development of a multifaceted treatment regimen in which we suggest using small molecules to inhibit three essential biological pathways important for the development of ARMS: 1) prevent phosphorylation of PAX3-FOXO1 at the key regulatory site; 2) kill aneuploid cells; and 3) inhibit at least one of the affected growth factor related pathways. Here, FOXO1 is linked to alveolar rhabdomyosarcoma.